Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Repligen Q3 2026 Results: Net Loss of $38.4M

Repligen reported a net loss of $38.4 million for the third quarter of 2026, primarily driven by a $41.2 million intangible asset impairment charge. Despite the loss, total revenue grew to $209.3 million for the quarter, up from $188.8 million in the prior year period, while cash provided by operating activities increased to $104.2 million for the first nine months of the year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue209.3188.8
Profit before tax-26.817.1
Net income-38.414.9
EPS (diluted, $ a share)$-0.68$0.26

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+10.9%
Operating margin-14.1%
Source

10-Q filed with the SEC, NASDAQ: RGEN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Repligen Corp: key numbers

Share price
$162.78Close, Nov 16
Market cap
$10.4B
Shares outstanding
63.92MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Repligen Corp

All →
4:02 PM ET 8-K
Loan & Debt

Repligen $1B Debt Financing with U.S. Bank Trust Company, National Association

Repligen Corporation issued $1.0 billion in 0.25% Convertible Senior Notes due 2031. The transaction included $541.4 million issued in exchange for existing 2028 notes and $458.6 million issued for cash to manage the company's debt maturity profile and capital structure.

Value
$1B
Counterparty
U.S. Bank Trust Company, National Association
Term
through Nov 2031
6:13 AM ET 8-K
Loan & Debt

Repligen $1B Debt Financing

Repligen Corporation entered into agreements to issue $1.0 billion in 0.25% Convertible Senior Notes due 2031. The transaction includes $541.4 million in notes issued to exchange existing 1.00% notes due 2028 and $458.6 million in notes issued for cash to new investors.

Value
$1B
Term
through Nov 2031
7:05 AM ET 8-K
Financial Results

Repligen Financial Results

Repligen Corporation reported record third-quarter 2026 revenue of $209.3 million, representing 11% reported and 12.5% organic growth. The company also announced the completion of its BioLife Solutions acquisition in October and raised its full-year 2026 revenue guidance to a range of $844-$852 million.

“We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End-market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book.”

Olivier Loeillot, President and Chief Executive Officer

“The completion of the BioLife acquisition in October marks a significant milestone for Repligen, and integration is progressing well. Early customer feedback has been very encouraging, and we have already taken actions to realize a sizable portion of our expected operating expense synergies. Our strong year-to-date performance, continued order momentum and the addition of BioLife give us confidence to raise our full-year guidance again.”

Olivier Loeillot, President and Chief Executive Officer
4:18 PM ET Form 4
Insider Selling

Repligen CEO Olivier Loeillot Sells $1.04M of Stock

Olivier Loeillot, CEO, sold 5,535 shares of Repligen Corp at $178.75 to $190.00 a share (average $187.29) in 2 transactions, worth $1.04M in total on Oct 5, 2026. Shares held after the trade: 45,788 (-8.4%).

Value
$1.04M
Shares
5,535
Average price
$187.29
Role
CEO
Holding change
-8.4%
Trade date
Oct 5, 2026
9:14 AM ET 8-K
M&A Deal

Repligen M&A Deal with BioLife Solutions, Inc.

Repligen Corporation completed its acquisition of BioLife Solutions, Inc., a developer of cell processing tools for the cell and gene therapy market. Under the terms of the merger, BioLife stockholders received $11.25 in cash and 0.1442 shares of Repligen common stock for each share held. The deal expands Repligen's presence in the cell therapy workflow by adding BioLife's biopreservation media portfolio, including the CryoStor product line.

Counterparty
BioLife Solutions, Inc.

“BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies.”

Olivier Loeillot, President and Chief Executive Officer of Repligen
4:04 PM ET 8-K
Leadership Change

Repligen Leadership Change

Karen A. Dawes notified Repligen Corporation of her retirement from the Board of Directors, effective September 30, 2026. Her departure follows over twenty years of service and the completion of a successful CEO transition. The company stated the retirement is not due to any disagreement regarding operations, policies, or procedures.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.